The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

The goal of obesity management is to improve health. Sustained weight loss of more than
10% overall bodyweight improves many of the complications associated with obesity (eg …

The prevalence of obesity and diabetes mellitus (DM) has been consistently increasing
worldwide. Sharing powerful genetic and environmental features in their pathogenesis …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

Background According to current consensus guidelines for type 2 diabetes management,
bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Background This study aimed to investigate the prevalence and management of diabetes
mellitus, risk-factor control, and comorbidities among Korean adults. Methods We conducted …

Background Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin
analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA …

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for
chronic weight management provides a novel effective strategy against obesity. The reliable …